Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53

被引：1
|
作者：
Dumbrava, Ecaterina E.
Iwamoto, Fabio M.
Agulnik, Mark
Milhem, Mohammed
Tolcher, Anthony W.
Chugh, Rashmi
Demeure, Michael J.
Mita, Alain
Demel, Kurt
Diamond, Mark
Mirakhur, Beloo
Wilson, Laksmi
Oganesian, Aram
Chan, Danna
Keer, Harold N.
Taylor, Jason
Sims, Martin J.
Biondo, Andrea
Jueliger, Simone
Spira, Alexander
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT066
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT066
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical Significance of PICT1 in Patients of Hepatocellular Carcinoma with Wild-Type TP53
    Ishibashi, Masahisa
    Kogo, Ryunosuke
    Shibata, Kohei
    Ueo, Hiroki
    Uchi, Ryutaro
    Matsumura, Tae
    Takano, Yuki
    Sawada, Genta
    Takahashi, Yusuke
    Mima, Kousuke
    Kurashige, Junji
    Akiyoshi, Sayuri
    Iwaya, Takeshi
    Eguchi, Hidetoshi
    Sudo, Tomoya
    Sugimachi, Keishi
    Suzuki, Akira
    Wakabayashi, Go
    Mori, Masaki
    Mimori, Koshi
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : S537 - S544
  • [32] Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
    Fang, Shenying
    Krahe, Ralf
    Lozano, Guillermina
    Han, Younghun
    Chen, Wei
    Post, Sean M.
    Zhang, Baili
    Wilson, Charmaine D.
    Bachinski, Linda L.
    Strong, Louise C.
    Amos, Christopher I.
    [J]. PLOS ONE, 2010, 5 (05):
  • [33] A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
    Razak, Albiruni R. Abdul
    Miller, Wilson H., Jr.
    Uy, Geoffrey L.
    Blotner, Steven
    Young, Anne-Marie
    Higgins, Brian
    Chen, Lin-Chi
    Gore, Lia
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (04) : 1156 - 1165
  • [34] Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
    Stein, Eytan M.
    DeAngelo, Daniel J.
    Chromik, Joerg
    Chatterjee, Manik
    Bauer, Sebastian
    Lin, Chia-Chi
    Suarez, Cristina
    de Vos, Filip
    Steeghs, Neeltje
    Cassier, Philippe A.
    Tai, David
    Kiladjian, Jean-Jacques
    Yamamoto, Noboru
    Mous, Rogier
    Esteve, Jordi
    Minami, Hironobu
    Ferretti, Stephane
    Guerreiro, Nelson
    Meille, Christophe
    Radhakrishnan, Rajkumar
    Pereira, Bernard
    Mariconti, Luisa
    Halilovic, Ensar
    Fabre, Claire
    Carpio, Cecilia
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (05) : 870 - 881
  • [35] A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors
    Albiruni R. Abdul Razak
    Wilson H. Miller
    Geoffrey L. Uy
    Steven Blotner
    Anne-Marie Young
    Brian Higgins
    Lin-Chi Chen
    Lia Gore
    [J]. Investigational New Drugs, 2020, 38 : 1156 - 1165
  • [36] NEK2 promotes TP53 ubiquitination to enhance the proliferation and migration of TP53 wild-type glioblastoma cells
    Zhang, Yu
    Yu, Hao
    He, Mengyao
    Liu, Wenchao
    Xiao, Shengyou
    Wang, Xiangting
    Huang, Ping
    Huang, Qiang
    [J]. NEOPLASMA, 2024, 71 (03)
  • [37] Low SKP2 expression is predictive of sensitivity to an MDM2 antagonist in p53 wild-type AML
    Kucia-Tran, J.
    Bevan, L.
    Chessari, G.
    Fazal, L.
    Ferrari, N.
    Lyons, J.
    Saini, H.
    Wallis, N.
    Ward, G.
    Ahn, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2022, 174 : S83 - S84
  • [38] Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2-p53 antagonist
    Peltzer, Alexander
    Hesse, Raphael
    Gounder, Mrinal M.
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott
    Bauer, Todd Michael
    Teufel, Michael
    Geng, Junxian
    LoRusso, Patricia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] In vivo evaluation of the intravenous MDM2-p53 antagonist RO6839921 alone and in combination with temozolomide in TP53 wild-type orthotopic models of neuroblastoma
    Chen, Lindi
    Pastorino, Fabio
    Berry, Philip
    Bonner, Jennifer
    Wood, Katrina
    Veal, Gareth
    Ponzoni, Mirco
    Lunec, John
    Newell, David R.
    Tweddle, Deborah A.
    [J]. CANCER RESEARCH, 2017, 77
  • [40] Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
    Alimova, Irina
    Wang, Dong
    Danis, Etienne
    Pierce, Angela
    Donson, Andrew
    Serkova, Natalie
    Madhavan, Krishna
    Lakshmanachetty, Senthilnath
    Balakrishnan, Ilango
    Foreman, Nicholas K.
    Mitra, Siddhartha
    Venkataraman, Sujatha
    Vibhakar, Rajeev
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2022, 60 (03)
12345